Hou, Luqia
Kumar, Mohit
Anand, Priti
Chen, Yinhong
El-Bizri, Nesrine
Pickens, Chad J.
Seganish, W. Michael
Sadayappan, Sakthivel
Swaminath, Gayathri
Funding for this research was provided by:
Merck & Co., Inc., South San Francisco, CA, 94080, USA
American Heart Association Predoctoral Fellowship (17PRE33630192)
National Institutes of Health grants (R01 AR078001, R01 HL130356, R38 HL155775, R01 HL143490)
American Heart Association 2019 Institutional Undergraduate Student (19UFEL34380251)
American Heart Association 2019 Transformation (19TPA34830084)
Amgen
Novo Nordisk
AstraZeneca
MyoKardia
Merck
Article History
Received: 5 October 2021
Accepted: 3 March 2022
First Online: 14 March 2022
Competing interests
: Sakthivel Sadayappan provided consulting and collaborative research studies to the Leducq Foundation, Pfizer, Novo Nordisk, Amgen, AstraZeneca, MyoKardia, but such work is unrelated to the content of this manuscript. The authors declare that they have no conflicts of interest with the contents of this article.